Now, a team of scientists at Beth Israel Deaconess Medical Center (BIDMC) have assessed the long-term effects of intranasal insulin (INI) on cognition and on gait in people with and without type 2 diabetes mellitus. MemAID, a phase 2 randomized controlled clinical trial, provided evidence that intranasal insulin increased the walking speed, increased cerebral blood flow and decreased plasma insulin in participants with type 2 diabetes, while it improved decision making and verbal memory in trial participants without the disease and those with pre-diabetes. The findings, published in the Journal of Neurology, suggest intranasal insulin should be further tested for its possible utility as a treatment for type 2 diabetes as well as a treatment for age-related functional decline.
“Walking speed is an important clinical predictor of well-being in the elderly that correlates with cognitive decline, hospitalizations, disability and death,” said corresponding author Vera Novak, MD, Ph.D., of the Department of Neurology at BIDMC and an associate professor of neurology at Harvard Medical School. “At baseline, participants with diabetes walked slower and had worse cognition than the participants without diabetes, who served as a clinical reference for normal aging population.”
Novak and colleagues at BIDMC and BWH enrolled 223 participants ages 50 to 85-years-old with and without diabetes, and assessed their normal and dual-task walking speeds, attention, memory and executive function and mood using a battery of validated tests. Half of the participants with diabetes (n=51) and half without diabetes (n=58) were treated with insulin, delivered intranasally via an electronic atomizer once daily. A double-blinded trial, the other participants were given an inactive placebo (sterile saline) that was also delivered intranasally.
After 24 weeks of treatment participants with diabetes who received INI had faster-walking speeds during treatment and post-treatment than participants with diabetes who received a placebo. The INI-treated participants with diabetes also demonstrated increased cerebral blood flow in the frontal lobe, and lower plasma insulin and insulin resistance compared to the placebo group, while the INI-treated participants without diabetes showed improved decision making and verbal memory. Combined, the INI-treated participants both with and without type 2 diabetes demonstrated faster walking and better executive functioning and memory, with those with pre-diabetes showing the most marked improvements in decision making and verbal memory.
“The consistency of the trends in the data showing better performance on walking speed and cognition for INI-treated participants, especially in those with pre-diabetes, carries great implication for potential early intervention using INI in this population to prevent or slow down the progression toward Alzheimer’s Disease-related dementias,” said Long Ngo, Ph.D., senior author of the study and co-director of Biostatistics Division of General Medicine at BIDMC, as well as associate professor of medicine and biostatistics at Harvard Medical School, and Harvard T.H. Chan School of Public Health. “With 96 million adult Americans, and increasing number of younger people having pre-diabetes, this finding on the beneficial effect of INI deserves more attention and definitive confirmation in a larger trial.”
The treatment was not associated with any serious or moderate adverse events. Intranasal insulin treatment was safe in participants with type 2 diabetes treated with subcutaneous insulins.
Co-authors included Christos S. Mantzoros, MD, Dsc, Vasileios Lioutas, MD, Stephanie Buss, MD, Faizan Khan, MD, and Laura Aponte Becerra, MD, of BIDMC; Peter Novak, MD, Ph.D. – Site Principal Investigator of Brigham and Women’s Hospital; Regina McGlinchey Ph.D. – Site Principal Investigator, and Catherine B. Fortier, Ph.D., of VA Boston Healthcare System and Harvard Medical School; and Weiying Dai, Ph.D., of State University of New York, Binghamton.
Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIIDDK) under award number R01DK103902 (FDA IND 107690) and with support from Harvard Catalyst – The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health award UL1TR002541) and financial contributions from Harvard University and its affiliated academic health care centers. This research study was supported with a study drug from Novo Nordisk, Inc., through an independent ISS grant (ISS-001063) to V. Novak. Safety sub-study was supported with CGM monitoring devices and supplies from Medtronic Inc., through an independent grant NERP 15-031 to V. Novak. Novo Nordisk, Inc., and Medtronic, Inc., reviewed the manuscript, but had no participation in data analysis, manuscript preparation or submission decision.
V. Novak, McGlinchey, Fortier, Dai, Khan and Aponte Becerra report no disclosures relevant to the manuscript. Mantzoros provided consultations for Coherus, AltrixBio, California Walnut Commission, Genfit, Regeneron, Ansh, Amgen, Intercept and Aegerion. Mantzoros has provided educational services through Elsevier, CMHC, TMIOA (all unrelated to this project since 2015 through 2020). Mantzoros provided consultations for Novo Nordisk, Inc., on Obesity Advisory Board, and has received grant support through BIDMC which could be considered as related to this project, given that Novo Nordisk, Inc. provided medication. Ngo provided consultation to the Radiological Society, the Journal of Cardiovascular Magnetic Resonance, Five Island Consulting LLC, and to Vinmec Inc. between 2015 and 2020. For a full list of disclosures, please read the study at the Journal of Neurology.
